|
 |
||
      |
|
|
» Apply for a Grant
- FAQs - Young Investigator - Independent Investigator - Distinguished Investigator - Staglin Award » Grantee List - Young Investigators - Independent Investigators - Distinguished Investigators - Staglin Awards
» Prizes
- Lieber Prize - Falcone Prize - Ruane Prize - Goldman-Rakic Prize - Freedman Award - Klerman Award » For Grantees - Young Investigator Fact Sheet - Independent Investigator Fact Sheet - Distinguished Investigator Fact Sheet - Staglin Award Fact Sheet 
|
 Project Summary  Felix Hasler, Ph.D. (Young Investigator 2004) of Psychiatric University Hospital, Zurich, seeks to elucidate the mode of interaction of serotonergic 5-HT1A and 5-HT2A receptors in humans by exploring the effects of psilocybin, a 5HT2A agonist. The functional integrity of 5-HT2A and 5-HT1A serotonin (5-HT) receptors is crucial in the pathophysiology of schizophrenia. Dr. Hasler hypothesizes that it is conceivable that partial 5-HT1A agonists may ameliorate psychotic symptoms and cognitive deficits in schizophrenic psychoses. He will attempt to understand the mode of interaction of serotonergic 5-HT1A and 5-HT2A receptors in humans and its basic and clinical implications. Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia |
Announcements
NARSAD Award Winners
 Colleen Ann McClung, Ph.D., UT Southwestern Medical Center at Dallas, 2005 & 2007 Young Investigator Latest News from NARSAD
|
